Table 2.
Patient characteristics and rate of CTC status of HER2-nonamplified patients (No HER2 therapy) divided by palliative therapy before enrollment
| Chemotherapy before enrollment | Endocrine therapy before enrollment | No therapy before enrollment | p | ||
|---|---|---|---|---|---|
| Total | n | 144 | 19 | 49 | |
| ≥ 1 CTC at enrollment | Rate | 73.6% | 52.6% | 53.1% | 0.012 |
| ≥ 5 CTC at enrollment | Rate | 54.2% | 26.3% | 30.6% | 0.003 |
| ≥ 1 HER2-positive CTC at enrollment | Rate | 2.8% | 0.0% | 6.1% | 0.369 |
| ≥ 1 CTC after 4 weeks | Rate | 57.6% | 26.3% | 38.8% | 0.006 |
| ≥ 5 CTC after 4 weeks | Rate | 36.8% | 10.5% | 24.5% | 0.032 |
| ≥ 1 HER2-positive CTC after 4 weeks | Rate | 2.8% | 0.0% | 0.0% | 0.062 |
| PD after 3 months | n | 47 | 3 | 10 | |
| Rate | 32.6% | 15.8% | 20.4% | 0.116 | |
| Age at diagnosis BC |
Mean (95% CI) |
50.0 years (48.3–51.7) |
56.5 years (51.5–61.4) |
55.0 years (51.6–58.5) |
0.014 |
| Age at enrollment |
Mean (95% CI) |
58.7 years (56.9–60.6) |
63.3 years (58.2–68.4) |
59.5 years (56.1–62.8) |
0.513 |
| Number CHT met |
Mean (95% CI) |
2.2 (1.9–2.4) |
0 (0.0–0.0) |
0 (0.0–0.0) |
< 0.001 |
| Endocrine therapy met | Rate | 63.2% | 100% | 0% | < 0.001 |
| PFS |
Mean (95% CI) |
10.4 months (8.0–12.8) |
13.4 months (7.3–19.5) |
9.9 months (7.0–12.8) |
0.955 |
| OS |
Mean (95% CI) |
24.8 months (21.1–28.5) |
30.5 months (22.3–38.8) |
31.0 months (26.0–35.9) |
0.065 |